Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma,Asia-Pacific Journal of Clinical Oncology

当前位置： X-MOL 学术 › Asia Pac. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma
Asia-Pacific Journal of Clinical Oncology ( IF 1.4 ) Pub Date : 2022-09-16 , DOI: 10.1111/ajco.13845
Nadia Hitchen _{1,

2} , Nick R Waldron ₁ , Sanjeev Deva _{1,

2} , Michael Findlay _{1,

2} , Benjamin Lawrence _{1,

2}

Affiliation

First-line palliative chemotherapy regimens in advanced pancreatic adenocarcinoma include triplet chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan, and the doublet of nab-paclitaxel plus gemcitabine. Use of triplet chemotherapy in real-world populations is limited by tolerability and nab-paclitaxel is not universally available. Regimens using the combination of cisplatin, capecitabine, gemcitabine, and either epirubicin or docetaxel may be better tolerated, more widely available, and similarly effective, but no published real-world data exist.

中文翻译：

顺铂、卡培他滨和吉西他滨联合表柔比星 (PEXG) 或多西他赛 (PDXG) 作为一线姑息治疗治疗转移性或不可切除的局部晚期胰腺癌的真实世界结果

晚期胰腺腺癌的一线姑息化疗方案包括 5-氟尿嘧啶、奥沙利铂和伊立替康的三联化疗，以及白蛋白结合型紫杉醇加吉西他滨的双联化疗。三联化疗在现实世界人群中的使用受到耐受性的限制，并且白蛋白结合型紫杉醇并非普遍可用。使用顺铂、卡培他滨、吉西他滨和表柔比星或多西他赛组合的治疗方案可能具有更好的耐受性、更广泛的应用且同样有效，但尚无公开的真实数据。

更新日期：2022-09-16

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11